Middle East & Africa Radiopharmaceutical Theranostics Market Forecast to 2028
Middle East & Africa Radiopharmaceutical Theranostics Market Forecast to 2028 – Regional Analysis – by Product Type (Alpha Emitters, Beta Emitters, and Positron Emission Tomography (PET) Tracers), Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others); Source (Nuclear Reactors and Cyclotrons), Application (Targeted Therapeutic [Rx] and Companion Diagnostic [CDx]); Indication (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Diagnostic Imaging Centers, Academic and Research Institutes, and Others)
$2,100 – $3,500
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Rising Incidence of Cancer fuel the Middle East & Africa Radiopharmaceutical Theranostics Market
The most common types of cancer are breast, lung, colon, rectum, and prostate. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include 43/44 Sc/47 Sc, 64 Cu/67 Cu, 83 Sr/89 Sr, 86Y/90 Y, 110 In/111 In, 124I/131 I, 152 Tb/161 Tb, 152 Tb/149 Tb, 68 Ga/177 Lu, and 90 Y/177 Lu. 123 I/131 I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer. Malignant gliomas are deadly tumors with the availability of only a few therapeutic options. 89 Zr- and 177 Lu-labeled Lumi804-αCD11b is a promising theranostic technique intended for monitoring and reducing tumor-associated myeloid cells (TAMCs) in gliomas and improving immunotherapy outcomes. Further, theranostics are incorporated in radiometals for PET imaging and targeted radiopharmaceutical therapy (TRT). DOTA-octreotate (dotatate) radiolabeled with Lu-177 (177Lu-dotatate: Lutathera) or Ga-68 (68Ga-dotatate: NetSpot) are approved by the Food and Drug Administration (FDA) for targeted radiopharmaceutical therapy (TRT) and positron emission tomography (PET) imaging. Thus, a radiopharmaceutical theranostic approach has unprecedented value in diagnosing and treating different types of cancer, which fuels the overall market growth.
Middle East & Africa Radiopharmaceutical Theranostics Market Overview
The Middle East & Africa radiopharmaceutical theranostics market is segmented into the Saudi Arabia, South Africa, UAE, and the rest of Middle East & Africa. The market growth in this region is due to the increasing incidences of chronic diseases, presence of supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies. The major factors for diabetes are obesity, unhealthy lifestyle, increased life expectancy, increased healthcare expenditures, and genetic susceptibility. Thus, increasing cardiovascular diseases due to rising diabetes condition in Saudi Arabia is driving the growth of radiopharmaceutical theranostics market.
Middle East & Africa Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)
Middle East & Africa Radiopharmaceutical Theranostics Market Segmentation
The Middle East & Africa radiopharmaceutical theranostics market is segmented based on product type, radioisotype, source, application, indication, end user, and country. Based on product type, the Middle East & Africa radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The Positron Emission Tomography (PET) tracers segment held the largest market share in 2022.
Based on radioisotype, the Middle East & Africa radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the Middle East & Africa radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the Middle East & Africa radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held a larger market share in 2022.
Based on indication, the Middle East & Africa radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the Middle East & Africa radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022.
Based on country, the Middle East & Africa radiopharmaceutical theranostics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa radiopharmaceutical theranostics market share in 2022.
Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers are some of the leading companies operating in the Middle East & Africa radiopharmaceutical theranostics market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Publishing status: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team research, the Middle East & Africa radiopharmaceutical theranostics market was valued at US$ 89.44 million in 2022 and is expected to reach US$ 157.30 million by 2028, registering a CAGR of 9.9% from 2022 to 2028. Rising incidence of cancer and rising application in treatment of cardiovascular disorders are the critical factors attributed to the Middle East & Africa radiopharmaceutical theranostics market expansion.
Cardiovascular diseases (CVDs) are among the most prevalent chronic diseases of the 21st century, with a high mortality rate. Due to their sedentary lifestyle, CVDs are the leading cause of mortality and morbidity in developed countries. In addition, obesity and diabetes, and related diseases are associated with cardiovascular disease and are becoming comorbid. In addition, a complication such as coronary artery obstruction is one of the number one causes of death in adults, resulting in thrombus plaque in the intima of the arterial wall, mainly in the carotid artery. Therapeutic applications in cardiovascular diseases include nanomedicine in angina pectoris, myocarditis, myocardial infarction, pericardial disease, thrombosis, atherosclerosis, hyperlipidemia, hypertension, pulmonary arterial hypertension, and stroke. Theranostic nanomedicines can prolong systemic circulation, evade host defense systems, and deliver theranostic agents to the target site for imaging and therapy at the cellular and molecular levels. A National Institute of Health (NIH) report states that theranostic nanoparticles have gained significant attention in the medical field, as the techniques help overcome complexities and pathophysiological complications associated with CVDs. Cardiovascular imaging of atherosclerosis patients provides pathophysiological evidence that can help treat CVDs. Further, theranostic nanoparticles can be combined with a range of imaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT). Various clinical research studies have been conducted in clinical laboratories so far. A three-in-one therapeutic complex has been constructed, by combining a polymeric photoacoustic probe with nanoparticles-PLCDP@PMH. Clinical in-vivo evaluations reveal that the PLCDP@PMH provides lucrative advantages for the theranostics approach to early-stage atherosclerosis detection in patients. This is expected to drive the Middle East & Africa radiopharmaceutical theranostics market during the forecast period.
On the contrary, regulatory challenges for approval of radiopharmaceutical theranostics hurdles the growth of Middle East & Africa radiopharmaceutical theranostics market.
Based on product type, the Middle East & Africa radiopharmaceutical theranostics market is categorized into alpha emitters, beta emitters, and positron emission tomography (PET) tracers. The positron emission tomography (PET) tracers segment held 45.9% market share in 2022, amassing US$ 41.02 million. It is projected to garner US$ 74.34 million by 2028 to expand at 10.4% CAGR during 2022–2028.
Based on radioisotope, the Middle East & Africa radiopharmaceutical theranostics market is categorized into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18 (18F), yttrium 90 (Y-90), Lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held 25.0% market share in 2022, amassing US$ 22.39 million. It is projected to garner US$ 41.77 million by 2028 to expand at 11.0% CAGR during 2022–2028.
Based on source, the Middle East & Africa radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held 54.8% market share in 2022, amassing US$ 48.99 million. It is projected to garner US$ 91.98 million by 2028 to expand at 11.1% CAGR during 2022–2028.
Based on application, the Middle East & Africa radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held 63.9% market share in 2022, amassing US$ 57.17 million. It is projected to garner US$ 101.93 million by 2028 to expand at 10.1% CAGR during 2022–2028.
Based on indication, the Middle East & Africa radiopharmaceutical theranostics market is categorized into oncology, cardiology, neurology, and others. The oncology segment held 61.7% market share in 2022, amassing US$ 55.15 million. It is projected to garner US$ 100.40 million by 2028 to expand at 10.5% CAGR during 2022–2028.
Based on end user, the Middle East & Africa radiopharmaceutical theranostics market is categorized into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held 35.0% market share in 2022, amassing US$ 31.33 million. It is projected to garner US$ 54.21 million by 2028 to expand at 9.6% CAGR during 2022–2028.
Based on country, the Middle East & Africa radiopharmaceutical theranostics market has been categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 40.5% share of Middle East & Africa radiopharmaceutical theranostics market in 2022. It was assessed at US$ 36.23 million in 2022 and is likely to hit US$ 66.43 million by 2028, exhibiting a CAGR of 10.6% during 2022–2028.
Key players operating in the Middle East & Africa radiopharmaceutical theranostics market are Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers among others.
In Aug 2021, Bayer strengthened drug discovery platform through acquisition of Vividion Therapeutics. In Feb 2022, Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africaradiopharmaceutical theranostics market.
o Highlights key business priorities in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africaradiopharmaceutical theranostics market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africaradiopharmaceutical theranostics market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Research Team Report Guidance
1.3 Market Segmentation
1.3.1 Middle East & Africa Radiopharmaceutical Theranostics Market – by Product Type
1.3.2 Middle East & Africa Radiopharmaceutical Theranostics Market – by Radioisotope
1.3.3 Middle East & Africa Radiopharmaceutical Theranostics Market – by Source
1.3.4 Middle East & Africa Radiopharmaceutical Theranostics Market – by Application
1.3.5 Middle East & Africa Radiopharmaceutical Theranostics Market – by Indication
1.3.6 Middle East & Africa Radiopharmaceutical Theranostics Market – by End User
1.3.7 Middle East & Africa Radiopharmaceutical Theranostics Market – by Country
2. Middle East & Africa Radiopharmaceutical Theranostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Radiopharmaceutical Theranostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Middle East & Africa PEST Analysis
4.3 Expert’s Opinion
5. Middle East & Africa Radiopharmaceutical Theranostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Incidence of Cancer
5.1.2 Rising Application in Treatment of Cardiovascular Disorders
5.2 Market Restraints
5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
5.3 Market Opportunities
5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
5.4 Future Trends
5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
5.5 Impact Analysis
6. Radiopharmaceutical Theranostics Market – Middle East & Africa Analysis
6.1 Middle East & Africa Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis
7. Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 – by Product Type
7.1 Overview
7.2 Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
7.2.1 Positron Emission Tomography (PET) Tracers
7.2.1.1 Overview
7.2.1.2 Positron Emission Tomography (PET) Tracers: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
7.2.2 Beta Emitters
7.2.2.1 Overview
7.2.2.2 Beta Emitters: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
7.2.3 Alpha Emitters
7.2.3.1 Overview
7.2.3.2 Alpha Emitters: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis – by Radioisotope
8.1 Overview
8.2 Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
8.2.1 Technetium-99
8.2.1.1 Overview
8.2.1.2 Technetium-99: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.2 Gallium-68
8.2.2.1 Overview
8.2.2.2 Gallium-68: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.3 Iodine-131
8.2.3.1 Overview
8.2.3.2 Iodine-131: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4 Iodine-123
8.2.4.1 Overview
8.2.4.2 Iodine-123: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.5 Fluorine-18 (18F)
8.2.5.1 Overview
8.2.5.2 Fluorine-18 (18F): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.6 Yttrium 90 (Y-90)
8.2.6.1 Overview
8.2.6.2 Yttrium 90 (Y-90): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.7 Lutetium (LU) 177
8.2.7.1 Overview
8.2.7.2 Lutetium (LU) 177: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.8 Copper (CU) 67
8.2.8.1 Overview
8.2.8.2 Copper (CU) 67: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.9 Copper (CU) 64
8.2.9.1 Overview
8.2.9.2 Copper (CU) 64: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.10 Others
8.2.10.1 Overview
8.2.10.2 Others: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
9. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis – by Source
9.1 Overview
9.2 Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
9.2.1 Nuclear Reactors
9.2.1.1 Overview
9.2.1.2 Nuclear Reactors: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.2 Cyclotrons
9.2.2.1 Overview
9.2.2.2 Cyclotrons: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
10. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis – by Application
10.1 Overview
10.2 Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
10.2.1 Targeted Therapeutic (Rx)
10.2.1.1 Overview
10.2.1.2 Targeted Therapeutics (Rx): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
10.2.2 Companion Diagnostic (CDx)
10.2.2.1 Overview
10.2.2.2 Companion Diagnostics (CDx): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis – by Indication
11.1 Overview
11.2 Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
11.2.1 Oncology
11.2.1.1 Overview
11.2.1.2 Oncology: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11.2.2 Neurology
11.2.2.1 Overview
11.2.2.2 Neurology: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11.2.3 Cardiology
11.2.3.1 Overview
11.2.3.2 Cardiology: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11.2.4 Others
11.2.4.1 Overview
11.2.4.2 Others: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis – by End User
12.1 Overview
12.2 Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
12.2.1 Hospitals
12.2.1.1 Overview
12.2.1.2 Hospitals: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12.2.2 Diagnostic Imaging Centers
12.2.2.1 Overview
12.2.2.2 Diagnostic Imaging Centers: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12.2.3 Academic & Research Institutes
12.2.3.1 Overview
12.2.3.2 Academic & Research Institutes: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12.2.4 Others
12.2.4.1 Overview
12.2.4.2 Others: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13. Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 – by Country Analysis
13.1 Middle East & Africa Radiopharmaceutical Theranostics Market
13.1.1 Overview
13.1.2 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
13.1.2.1 Saudi Arabia: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.1.1 Overview
13.1.2.1.2 Saudi Arabia Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.1.3 Saudi Arabia Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US$ Million)
13.1.2.1.4 Saudi Arabia Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US$ Million)
13.1.2.1.5 Saudi Arabia Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US$ Million)
13.1.2.1.6 Saudi Arabia Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US$ Million)
13.1.2.1.7 Saudi Arabia Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US$ Million)
13.1.2.1.8 Saudi Arabia Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US$ Million)
13.1.2.2 South Africa: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.2.1 Overview
13.1.2.2.2 South Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.2.3 South Africa Radiopharmaceutical Theranostics Market, by Product type, 2019–2028 (US$ Million)
13.1.2.2.4 South Africa Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US$ Million)
13.1.2.2.5 South Africa Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US$ Million)
13.1.2.2.6 South Africa Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US$ Million)
13.1.2.2.7 South Africa Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US$ Million)
13.1.2.2.8 South Africa Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US$ Million)
13.1.2.3 UAE: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.3.1 Overview
13.1.2.3.2 UAE Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.3.3 UAE Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US$ Million)
13.1.2.3.4 UAE Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US$ Million)
13.1.2.3.5 UAE Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US$ Million)
13.1.2.3.6 UAE Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US$ Million)
13.1.2.3.7 UAE Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US$ Million)
13.1.2.3.8 UAE Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US$ Million)
13.1.2.4 Rest of Middle East & Africa: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.4.1 Overview
13.1.2.4.2 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.4.3 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US$ Million)
13.1.2.4.4 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US$ Million)
13.1.2.4.5 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US$ Million)
13.1.2.4.6 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US$ Million)
13.1.2.4.7 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US$ Million)
13.1.2.4.8 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US$ Million)
14. Radiopharmaceutical Theranostics Market – Industry Landscape
14.1 Overview
14.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
14.3 Inorganic Growth Strategies
14.3.1 Overview
14.4 Organic Growth Strategies
14.4.1 Overview
15. Company Profiles
15.1 Bayer AG
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Curium
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Telix Pharmaceuticals Ltd.
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Siemens Healthineers AG
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
16. Appendix
16.1 About The Insight Partners
16.2 Glossary of Terms
LIST OF TABLES
Table 1. Saudi Arabia Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. Saudi Arabia Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US$ Million)
Table 3. Saudi Arabia Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 4. Saudi Arabia Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 5. Saudi Arabia Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 6. Saudi Arabia Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. South Africa Radiopharmaceutical Theranostics Market, by Product type – Revenue and Forecast to 2028 (US$ Million)
Table 8. South Africa Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US$ Million)
Table 9. South Africa Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 10. South Africa Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 11. South Africa Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 12. South Africa Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 13. UAE Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. UAE Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US$ Million)
Table 15. UAE Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 16. UAE Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 17. UAE Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 18. UAE Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 20. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 24. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 25. Recent Inorganic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 26. Recent Organic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 27. Glossary of Terms
LIST OF FIGURES
Figure 1. Middle East & Africa Radiopharmaceutical Theranostics Market Segmentation
Figure 2. Middle East & Africa Radiopharmaceutical Theranostics Market, by Country
Figure 3. Middle East & Africa Radiopharmaceutical Theranostics Market Overview
Figure 4. Positron Emission Tomography (PET) Tracers Segment Held Largest Share of Product Type Segment in Radiopharmaceutical Theranostics Market
Figure 5. Saudi Arabia Expected to Show Remarkable Growth During Forecast Period
Figure 6. Middle East & Africa: PEST Analysis
Figure 7. Middle East & Africa Experts’ Opinion
Figure 8. Middle East & Africa Radiopharmaceutical Theranostics Market: Impact Analysis of Drivers and Restraints
Figure 9. Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue Forecast and Analysis – 2020–2028
Figure 10. Middle East & Africa Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 11. Positron Emission Tomography (PET) Tracers: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Beta Emitters: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Alpha Emitters: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope, 2021 & 2028 (%)
Figure 15. Technetium-99: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Gallium-68: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Iodine-131: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Iodine-123: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Fluorine-18 (18F): Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Yttrium 90 (Y-90): Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Lutetium (LU) 177: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Copper (CU) 67: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Copper (CU) 64: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Others: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Middle East & Africa Radiopharmaceutical Theranostics Market, by Source, 2021 & 2028 (%)
Figure 26. Nuclear Reactors: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Cyclotrons: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Middle East & Africa Radiopharmaceutical Theranostics Market, by Application, 2021 & 2028 (%)
Figure 29. Targeted Therapeutics (Rx): Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Companion Diagnostics (CDx): Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication, 2021 & 2028 (%)
Figure 32. Oncology: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Neurology: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Cardiology: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Others: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Middle East & Africa Radiopharmaceutical Theranostics Market, by End User, 2021 & 2028 (%)
Figure 37. Hospitals: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Diagnostic Imaging Centers: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Academic & Research Institutes: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Others: Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Middle East & Africa: Radiopharmaceutical Theranostics Market, by Key Country – Revenue (2021) (US$ Million)
Figure 42. Saudi Arabia Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. South Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. UAE Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 46. Growth Strategies in the Radiopharmaceutical Theranostics Market
The List of Companies – Middle East & Africa Radiopharmaceutical Theranostics Market
o Bayer AG
o Curium
o Telix Pharmaceuticals Ltd.
o Siemens Healthineers
You must be logged in to post a review.
Reviews
There are no reviews yet.